Patent ID: 9296690
Filing Date: 2016-03-29
CPC Classification: A61K,A61P,C07D

Claim Text:
1. A method of treating metabolic bone disease, the method comprising: single or multiple administration of a pharmaceutical composition comprising the compound selected from the group consisting of: 1-(2,6-diisopropylphenyl)-3,4-diphenyl-1H-pyrrole-2,5-dione; 1,3,4-triphenyl-1H-pyrrole-2,5-dione; 1-(2-chlorophenyl)-3,4-diphenyl-1H-pyrrole-2,5-dione; 1-(3-chlorophenyl)-3,4-diphenyl-1H-pyrrole-2,5-dione; 1-(4-chlorophenyl)-3,4-diphenyl-1H-pyrrole-2,5-dione; 3,4-diphenyl-1-(2-(trifluoromethyl)phenyl)-1H-pyrrole-2,5-dione; 1-cyclohexyl-3,4-diphenyl-1H-pyrrole-2,5-dione; 4-(2,5-dioxo-3,4-diphenyl-2,5-dihydro-1H-pyrrol-1-yl)-2-hydroxybenzoic acid; 5-(2,5-dioxo-3,4-diphenyl-2,5-dihydro-1H-pyrrol-1-yl)-2-hydroxybenzoic acid; 3-chloro-1,4-diphenyl-1H-pyrrole-2,5-dione; 3-chloro-1-(2-chlorophenyl)-4-phenyl-1H-pyrrole-2,5-dione; 3-chloro-1-(3-chlorophenyl)-4-phenyl-1H-pyrrole-2,5-dione; 3-chloro-1-(4-chlorophenyl)-4-phenyl-1H-pyrrole-2,5-dione; 1-(2-fluorophenyl)-3,4-diphenyl-1H-pyrrole-2,5-dione; 1-(3-fluorophenyl)-3,4-diphenyl-1H-pyrrole-2,5-dione; 1-(4-fluorophenyl)-3,4-diphenyl-1H-pyrrole-2,5-dione; 1-benzyl-3,4-diphenyl-1H-pyrrole-2,5-dione; 1-(2-fluorobenzyl)-3,4-diphenyl-1H-pyrrole-2,5-dione; 1-(3-fluorobenzyl)-3,4-diphenyl-1H-pyrrole-2,5-dione; 1-(4-fluorobenzyl)-3,4-diphenyl-1H-pyrrole-2,5-dione; 1-phenethyl-3,4-diphenyl-1H-pyrrole-2,5-dione; 1-(2-fluorophenethyl)-3,4-diphenyl-1H-pyrrole-2,5-dione; 1-(3-fluorophenethyl)-3,4-diphenyl-1H-pyrrole-2,5-dione; 1-(4-fluorophenethyl)-3,4-diphenyl-1H-pyrrole-2,5-dione; 3-(2-chlorophenyl)-1-(4-chlorophenyl)-4-phenyl-1H-pyrrole-2,5-dione; 3-(3-chlorophenyl)-1-(4-chlorophenyl)-4-phenyl-1H-pyrrole-2,5-dione; 1,3-bis(4-chlorophenyl)-4-phenyl-1H-pyrrole-2,5-dione; 1-(4-chlorophenyl)-3-(2,6-dichlorophenyl)-4-phenyl-1H-pyrrole-2,5-dione; 1-(4-chlorophenyl)-5-hydroxy-3,4-diphenyl-1H-pyrrol-2(5H)-one; 1-(4-chlorophenyl)-3,4-diphenyl-1H-pyrrol-2(5H)-one; 1-(4-chlorophenyl)-3-((dimethylamino)methyl)-3,4-diphenylpyrrolidin-2-one; 3-hydroxy-1,4-diphenyl-1H-pyrrole-2,5-dione; 1-(4-chlorophenyl)-3-phenyl-4-(thiophen-2-yl)-1H-pyrrole-2,5-dione; 4-chloro-5-hydroxy-1,3-diphenyl-1H-pyrrol-2(5H)-one; and 1-(4-chlorophenyl)-3,4-diphenyl-2,5-dihydro-1H-pyrrole; or pharmaceutically acceptable salts thereof, wherein the metabolic bone disease is selected from the group consisting of bone metastatic cancer, solid cancer bone metastasis, musculoskeletal complication by solid cancer bone metastasis, hypercalcemia by malignant tumor, multiple myeloma, primary bone tumor, osteoporosis, Rheumatoid Arthritis, Osteoarthritis, Periodontal Disease, inflammatory resorption of alveolar bone, inflammatory resorption of bone and Paget's disease.